Clinical trials in regenerative medicine : negotiating process, practice and outcomes

There has been significant progress in the basic science of regenerative medicine over the past two decades, but clinical translation has been more halting. Clinical trials are a key step in the translational process and have been highlighted as a particular challenge for the field. This thesis adop...

Full description

Bibliographic Details
Main Author: Higham, Ruchi
Other Authors: Webster, Andrew ; Genever, Pail
Published: University of York 2017
Subjects:
301
Online Access:https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.739926
id ndltd-bl.uk-oai-ethos.bl.uk-739926
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-7399262019-03-05T15:29:19ZClinical trials in regenerative medicine : negotiating process, practice and outcomesHigham, RuchiWebster, Andrew ; Genever, Pail2017There has been significant progress in the basic science of regenerative medicine over the past two decades, but clinical translation has been more halting. Clinical trials are a key step in the translational process and have been highlighted as a particular challenge for the field. This thesis adopts an analytical framework informed by Jasanoff's idiom of co-production to investigate trials of one particular type of regenerative medicine: cell therapies. A mixed-methods design was used, which included quantitative analysis of secondary data, 17 semi-structured interviews with cell therapy trialists, and a longitudinal observational study of a cell therapy trial. The findings indicate that the cell therapy trials landscape in the UK is small, fragmented and dominated by academic-led, publicly-funded studies. This conflicts with a policy environment that is largely aligned with a commercial development model, and a trials process that was designed for drug trials funded by large corporations. Trials tend to be affected by a specific set of local factors, the most important being financial constraints, the logistics of working with cells, the temporality of the trial and the need to align the work of disparate domains. These issues create a challenging translational environment, with the linearity and abstracted nature of the trials process conflicting with the recursive, situated nature of innovation. They also highlight the significant contingency involved in trials, which is at odds with the priority evidence-based medicine places on this supposedly neutral, objective method. Whilst cell therapy trials must without a doubt be held to the highest regulatory standards, it is also important that the clinical research framework takes into account the challenges they pose and the contingent nature of the evidence they generate, and the thesis concludes with some recommendations as to how this might be achieved.301University of Yorkhttps://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.739926http://etheses.whiterose.ac.uk/19879/Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 301
spellingShingle 301
Higham, Ruchi
Clinical trials in regenerative medicine : negotiating process, practice and outcomes
description There has been significant progress in the basic science of regenerative medicine over the past two decades, but clinical translation has been more halting. Clinical trials are a key step in the translational process and have been highlighted as a particular challenge for the field. This thesis adopts an analytical framework informed by Jasanoff's idiom of co-production to investigate trials of one particular type of regenerative medicine: cell therapies. A mixed-methods design was used, which included quantitative analysis of secondary data, 17 semi-structured interviews with cell therapy trialists, and a longitudinal observational study of a cell therapy trial. The findings indicate that the cell therapy trials landscape in the UK is small, fragmented and dominated by academic-led, publicly-funded studies. This conflicts with a policy environment that is largely aligned with a commercial development model, and a trials process that was designed for drug trials funded by large corporations. Trials tend to be affected by a specific set of local factors, the most important being financial constraints, the logistics of working with cells, the temporality of the trial and the need to align the work of disparate domains. These issues create a challenging translational environment, with the linearity and abstracted nature of the trials process conflicting with the recursive, situated nature of innovation. They also highlight the significant contingency involved in trials, which is at odds with the priority evidence-based medicine places on this supposedly neutral, objective method. Whilst cell therapy trials must without a doubt be held to the highest regulatory standards, it is also important that the clinical research framework takes into account the challenges they pose and the contingent nature of the evidence they generate, and the thesis concludes with some recommendations as to how this might be achieved.
author2 Webster, Andrew ; Genever, Pail
author_facet Webster, Andrew ; Genever, Pail
Higham, Ruchi
author Higham, Ruchi
author_sort Higham, Ruchi
title Clinical trials in regenerative medicine : negotiating process, practice and outcomes
title_short Clinical trials in regenerative medicine : negotiating process, practice and outcomes
title_full Clinical trials in regenerative medicine : negotiating process, practice and outcomes
title_fullStr Clinical trials in regenerative medicine : negotiating process, practice and outcomes
title_full_unstemmed Clinical trials in regenerative medicine : negotiating process, practice and outcomes
title_sort clinical trials in regenerative medicine : negotiating process, practice and outcomes
publisher University of York
publishDate 2017
url https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.739926
work_keys_str_mv AT highamruchi clinicaltrialsinregenerativemedicinenegotiatingprocesspracticeandoutcomes
_version_ 1718993601389658112